Taipei Medical University

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Tu SH
------>authors3_c=
------>paper_class1=1
------>Impact_Factor=5.684
------>paper_class3=2
------>paper_class2=1
------>vol=
------>confirm_bywho=None
------>insert_bywho=cmbsycl
------>Jurnal_Rank=12.1
------>authors4_c=
------>comm_author=1
------>patent_EDate=None
------>authors5_c=
------>publish_day=1
------>paper_class2Letter=0
------>page2=
------>medlineContent=
------>unit=E0104
------>insert_date=20091106
------>iam=7
------>update_date=None
------>author=???
------>change_event=2
------>ISSN=
------>authors_c=
------>score=500
------>journal_name=Breast Cancer Res Treat
------>paper_name=Increased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells
------>confirm_date=None
------>tch_id=083006
------>pmid=19655245
------>page1=
------>fullAbstract=Enolase-alpha (ENO-1) is a key glycolytic enzyme that has been used as a diagnostic marker to identify human lung cancers. To investigate the role of ENO-1 in breast cancer diagnosis and therapy, the mRNA levels of ENO-1 in 244 tumor and normal paired tissue samples and 20 laser capture-microdissected cell clusters were examined by quantitative real-time PCR analysis. Increased ENO-1 mRNA expression was preferentially detected in estrogen receptor-positive (ER+) tumors (tumor/normal ratio >90-fold) when compared to ER-negative (tumor/normal ratio >20-fold) tumor tissues. The data presented here demonstrate that those patients whose tumors highly expressed ENO-1 had a poor prognosis with greater tumor size (>2 cm, *P = .017), poor nodal status (N > 3, *P = .018), and a shorter disease-free interval (<==1 year, *P < .009). We also found that higher-expressing ENO-1 tumors confer longer distance relapse (tumor/normal ratio = 82.8-92.4-fold) when compared to locoregional relapse (tumor/normal ratio = 43.4-fold) in postsurgical 4-hydroxy-tamoxifen (4-OHT)-treated ER+ patients (*P = .014). These data imply that changes in tumor ENO-1 levels are related to clinical 4-OHT therapeutic outcome. In vitro studies demonstrated that decreasing ENO-1 expression using small interfering RNA (siRNA) significantly augmented 4-OHT (100 nM)-induced cytotoxicity in tamoxifen-resistant (Tam-R) breast cancer cells. These results suggest that downregulation of ENO-1 could be utilized as a novel pharmacological approach for overcoming 4-OHT resistance in breast cancer therapy.
------>tmu_sno=None
------>sno=22871
------>authors2=Chang CC
------>authors3=Chen CS
------>authors4=Tam KW
------>authors5=Wang YJ
------>authors6=Lee CH, Lin HW, Cheng TC, Huang CS, Chu JS, Shih NY, Chen LC, Leu SJ*, Ho YS*, Wu CH*
------>authors6_c=
------>authors=Tu SH
------>delete_flag=0
------>SCI_JNo=74480
------>authors2_c=
------>publish_area=0
------>updateTitle=Increased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells.
------>language=2
------>check_flag=None
------>submit_date=None
------>country=None
------>no=
------>patent_SDate=None
------>update_bywho=None
------>publish_year=2009
------>submit_flag=None
------>publish_month=10
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z